search
Back to results

Effects of Steroid Tapering on Functional Capacity and Neurocognition

Primary Purpose

Glioblastoma Multiforme

Status
Withdrawn
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Dexamethasone acetate
Dexamethasone
Sponsored by
Duke University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Glioblastoma Multiforme focused on measuring Randomized, Dexamethasone, Abbreviated, Protracted, Post-operatively

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. written informed consent prior to beginning specific protocol procedures,
  2. histologically proven GBM,
  3. status-post gross total resection or subtotal resection as indicated by < 2 cm of residual enhancing disease (subjects with unresectable, multifocal, and /or bulky disease will be excluded),
  4. >18 years and <70 years of age,
  5. Karnofsky performance index >70%,
  6. no documented cardiac, neurodegenerative, neuromuscular, or pulmonary disease,
  7. no contraindications to a 6-minute walk test,
  8. no contraindications to neurocognitive testing,
  9. primary treating physician approval, and
  10. no complications operatively or postoperatively that requires modification of dexamethasone dosing.
  11. receiving dexamethasone as standard of care.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Experimental

    Arm Label

    Protracted (30 days), Dexamethasone

    Abbreviated (14 days), dexamethasone

    Arm Description

    Participants will receive a protracted course (30 days) of dexamethasone after surgery.

    Participants will receive an abbreviated (14 days) course of dexamethasone after surgery.

    Outcomes

    Primary Outcome Measures

    Functional Capacity (6-minute walk test)
    The exercise test is designed to determine how far you can walk in six minutes. This test will take place at the PRT-BTC at Duke University Medical Center and/or Duke University Medical Center inpatient unit on 4100 or 4300 with appropriate medical supervision.

    Secondary Outcome Measures

    Neurocognitive Function
    A computerized neurocognitive test battery called CNS Vital Signs® including verbal memory test, visual memory test, finger tapping test, symbol digit coding, Stroop test, shifting attention test, continuous performance test.
    Skeletal Muscle Strength
    Isokinetic muscle strength for bilateral grip and bilateral quadriceps.
    Patient-Reported Outcomes (PROs)
    Assessed by standardized and validated questionnaires including: Depression (Beck Depression Inventory); Quality of Life (Functional Assessment of Cancer Therapy-Brain); Fatigue (Functional Assessment of Cancer Therapy-Fatigue); Cognition (Functional Assessment of Cancer Therapy-Cognition), Symptomalogy Index (Phone Questionnarie/Survery), Computerized Battery from CNS Vital Signs (Medical Outcomes Survey, Epworth Sleepiness Scale, Pittsburgh Sleep Quality Index, Zung Self-Rating Depression Scale).
    Body composition
    Body-mass index, weight, height, and circumference of the abdomen, hips, and quadriceps.
    Biochemical metabolic measurements
    Hematocrit (%), albumin (g/mL), fasting blood glucose (mg/dL), fasting insulin (micro IU/mL), insulin like growth facto binding protein 1 (IGFBP-1) (ng/mL), cystatin C (mg/dL), and retinol binding protein 4 (RBP-4).

    Full Information

    First Posted
    June 25, 2010
    Last Updated
    May 15, 2014
    Sponsor
    Duke University
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT01169415
    Brief Title
    Effects of Steroid Tapering on Functional Capacity and Neurocognition
    Official Title
    Effects of Dexamethasone Tapering Schedules on Functional Capacity and Neurocognition in Patients With Newly Diagnosed Glioblastoma Multiforme
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    May 2014
    Overall Recruitment Status
    Withdrawn
    Why Stopped
    Funding not obtained
    Study Start Date
    June 2010 (undefined)
    Primary Completion Date
    May 2014 (Actual)
    Study Completion Date
    May 2014 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Duke University

    4. Oversight

    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    Purpose and Objective: To compare the effects of either an abbreviated or protracted taper of dexamethasone on functional capacity in newly diagnosed glioblastoma multiforme (GBM) patients. To compare neurocognitive function in newly diagnosed GBM patients receiving either an abbreviated or protracted taper of dexamethasone. To compare skeletal muscle strength in newly diagnosed GBM patients receiving either an abbreviated or protracted taper of dexamethasone. To examine the association between functional capacity and neurocognitive function and patient-reported measures (i.e. quality of life, fatigue, etc.) in newly diagnosed GBM patient on either an abbreviated or protracted taper of dexamethasone. To examine the association between functional capacity and neurocognitive function and body composition measures (body-mass index, etc.) in newly diagnosed GBM patient on either an abbreviated or protracted taper of dexamethasone. To examine the association between functional capacity and neurocognitive function and biochemical metabolic measurements in newly diagnosed GBM patient on either an abbreviated or protracted taper of dexamethasone. All study endpoints will be assessed at three timepoints as follows: (1) initial assessment after surgery in the hospital, (2) second assessment at initial clinical visit at the Preston Robert Tisch Brain Tumor Center (PRT-BTC) at Duke, approximately 1 week post-operatively, and (3) third assessment at second clinical visit in the PRT-BTC at Duke, approximately 10 weeks post-operatively and after completion of radiotherapy. An additional fourth assessment will be obtained at 4 weeks post-operatively if the subject is undergoing radiotherapy here at Duke.
    Detailed Description
    The proposed study is a randomized controlled trial. After obtaining written informed consent, all participants will be randomized to either an abbreviated (14 days) or protracted (30 days) course of dexamethasone post-operatively.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Glioblastoma Multiforme
    Keywords
    Randomized, Dexamethasone, Abbreviated, Protracted, Post-operatively

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Masking
    None (Open Label)
    Allocation
    Randomized
    Enrollment
    0 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Protracted (30 days), Dexamethasone
    Arm Type
    Experimental
    Arm Description
    Participants will receive a protracted course (30 days) of dexamethasone after surgery.
    Arm Title
    Abbreviated (14 days), dexamethasone
    Arm Type
    Experimental
    Arm Description
    Participants will receive an abbreviated (14 days) course of dexamethasone after surgery.
    Intervention Type
    Drug
    Intervention Name(s)
    Dexamethasone acetate
    Other Intervention Name(s)
    Decadron
    Intervention Description
    Participants will receive a protracted (30 days) course of dexamethasone after surgery.
    Intervention Type
    Drug
    Intervention Name(s)
    Dexamethasone
    Other Intervention Name(s)
    Decadron
    Intervention Description
    Participants will receive a protracted (14 days) course of dexamethasone after surgery.
    Primary Outcome Measure Information:
    Title
    Functional Capacity (6-minute walk test)
    Description
    The exercise test is designed to determine how far you can walk in six minutes. This test will take place at the PRT-BTC at Duke University Medical Center and/or Duke University Medical Center inpatient unit on 4100 or 4300 with appropriate medical supervision.
    Time Frame
    10 weeks
    Secondary Outcome Measure Information:
    Title
    Neurocognitive Function
    Description
    A computerized neurocognitive test battery called CNS Vital Signs® including verbal memory test, visual memory test, finger tapping test, symbol digit coding, Stroop test, shifting attention test, continuous performance test.
    Time Frame
    10 weeks
    Title
    Skeletal Muscle Strength
    Description
    Isokinetic muscle strength for bilateral grip and bilateral quadriceps.
    Time Frame
    10 weeks
    Title
    Patient-Reported Outcomes (PROs)
    Description
    Assessed by standardized and validated questionnaires including: Depression (Beck Depression Inventory); Quality of Life (Functional Assessment of Cancer Therapy-Brain); Fatigue (Functional Assessment of Cancer Therapy-Fatigue); Cognition (Functional Assessment of Cancer Therapy-Cognition), Symptomalogy Index (Phone Questionnarie/Survery), Computerized Battery from CNS Vital Signs (Medical Outcomes Survey, Epworth Sleepiness Scale, Pittsburgh Sleep Quality Index, Zung Self-Rating Depression Scale).
    Time Frame
    10 weeks
    Title
    Body composition
    Description
    Body-mass index, weight, height, and circumference of the abdomen, hips, and quadriceps.
    Time Frame
    10 weeks
    Title
    Biochemical metabolic measurements
    Description
    Hematocrit (%), albumin (g/mL), fasting blood glucose (mg/dL), fasting insulin (micro IU/mL), insulin like growth facto binding protein 1 (IGFBP-1) (ng/mL), cystatin C (mg/dL), and retinol binding protein 4 (RBP-4).
    Time Frame
    10 weeks

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    70 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: written informed consent prior to beginning specific protocol procedures, histologically proven GBM, status-post gross total resection or subtotal resection as indicated by < 2 cm of residual enhancing disease (subjects with unresectable, multifocal, and /or bulky disease will be excluded), >18 years and <70 years of age, Karnofsky performance index >70%, no documented cardiac, neurodegenerative, neuromuscular, or pulmonary disease, no contraindications to a 6-minute walk test, no contraindications to neurocognitive testing, primary treating physician approval, and no complications operatively or postoperatively that requires modification of dexamethasone dosing. receiving dexamethasone as standard of care.
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Katherine B Peters, MD, PhD
    Organizational Affiliation
    Duke Health
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Learn more about this trial

    Effects of Steroid Tapering on Functional Capacity and Neurocognition

    We'll reach out to this number within 24 hrs